کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2403732 1102930 2011 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی ایمونولوژی
پیش نمایش صفحه اول مقاله
The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination
چکیده انگلیسی

Anti-tumor vaccination is being evaluated as a prophylactic and therapeutic strategy against cancer growth, dissemination (spreading) or recurrence. Although a large number of studies investigate in detail the identity of antigens to be used for efficacious immune intervention, there have been few studies investigating the optimal form for antigen to be used in the vaccine. Here we show in a mouse H-2d MHC background and for NY-ESO-1 that genetic (plasmid DNA) but not full length protein vaccine is capable of inducing a protective prophylactic anti-tumor cytotoxic T-cell immune response in vivo. Peptide vaccination using nominal MHC class I epitope adjuvanted with a Toll Like Receptor agonist such as stabilized RNA can also provide some anti-tumor protection. Our results highlight the idea that when evaluating the clinical efficacy of a cancer vaccine, not only the identity of the antigen but also the format of the vaccine is of the utmost importance.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 29, Issue 22, 17 May 2011, Pages 3832–3836
نویسندگان
, , , ,